Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjects

被引:9
作者
Kang, HW
Kim, DJ
Lee, MS
Kim, KW
Lee, MK
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol & Metab,Dept Med, Seoul, South Korea
[2] Hallym Hosp, Dept Internal Med, Inchon, South Korea
[3] Inje Univ, Coll Med, Dept Internal Med, Koyang, South Korea
关键词
impaired fasting glucose; impaired glucose tolerance; insulinogenic index; homeostasis model assessment of insulin resistance; obesity; diabetes mellitus;
D O I
10.1016/j.diabres.2004.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the clinical characteristics and predisposing metabolic abnormalities in the development of glucose intolerance and diabetes mellitus in obese and non-obese Korean subjects. Methods: Four hundred Korean subjects were classified into five groups according to degree of glucose tolerance by OGTT: NGT, IGT alone, IFG alone, IFG + IGT, and DM. The groups were also subdivided into obese and non-obese group according to body mass index. Insulin resistance was assessed by using homeostasis model assessment of insulin resistance (HOMA-R), and insulinogenic index was used as an index of early-phase insulin secretion. Results: Impaired early-phase insulin secretion was seen in non-obese IGT alone, IFG alone, and IFG + IGT, though more profound secretory defects were noted in IFG + IGT and DM. No significant difference were found in HOMA-R among nonobese IGT alone, IFG alone, or IFG + IGT, or in terms of early-phase insulin secretion in obese IGT alone, IFG alone, or IFG + IGT. However, the magnitude of insulin resistance differed in the obese group, IFG + IGT and DM being more insulin resistant than IGT alone or IFG alone. Conclusions: These results suggest that the predisposing metabolic abnormality in non-obese subjects with IGT alone or IFG alone and in progression to IFG + IGT might be deterioration of early phase insulin secretion, whereas insulin resistance might be the major contributory factor in obese subjects. The predisposing metabolic abnormality leading to diabetes in both obese and non-obese groups was deterioration of early-phase insulin secretion. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:180 / 187
页数:8
相关论文
共 34 条
[1]   Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[2]   EARLIER APPEARANCE OF IMPAIRED INSULIN-SECRETION THAN OF VISCERAL ADIPOSITY IN THE PATHOGENESIS OF NIDDM - 5-YEAR FOLLOW-UP OF INITIALLY NONDIABETIC JAPANESE-AMERICAN MEN [J].
CHEN, KW ;
BOYKO, EJ ;
BERGSTROM, RW ;
LEONETTI, DL ;
NEWELLMORRIS, L ;
WAHL, PW ;
FUJIMOTO, WY .
DIABETES CARE, 1995, 18 (06) :747-753
[3]   The relationship between glucose and incident cardiovascular events [J].
Coutinho, M ;
Gerstein, HC ;
Wang, Y ;
Yusuf, S .
DIABETES CARE, 1999, 22 (02) :233-240
[4]   LOSS OF THE 1ST PHASE INSULIN-RESPONSE TO INTRAVENOUS GLUCOSE IN SUBJECTS WITH PERSISTENT IMPAIRED GLUCOSE-TOLERANCE [J].
DAVIES, MJ ;
RAYMAN, G ;
GRENFELL, A ;
GRAY, IP ;
DAY, JL ;
HALES, CN .
DIABETIC MEDICINE, 1994, 11 (05) :432-436
[5]   PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW [J].
DEFRONZO, RA ;
BONADONNA, RC ;
FERRANNINI, E .
DIABETES CARE, 1992, 15 (03) :318-368
[6]   Phasic insulin release and metabolic regulation in type 2 diabetes [J].
Del Prato, S ;
Marchetti, P ;
Bonadonna, RC .
DIABETES, 2002, 51 :S109-S116
[7]  
*ECODE STUD GROUP, 1999, LANCET, V354, P616
[8]   Predictors of progression from impaired glucose tolerance to NIDDM - An analysis of six prospective studies [J].
Edelstein, SL ;
Knowler, WC ;
Bain, RP ;
Andres, R ;
BarrettConnor, EL ;
Dowse, GK ;
Haffner, SM ;
Pettitt, DJ ;
Sorkin, JD ;
Muller, DC ;
Collins, VR ;
Hamman, RF .
DIABETES, 1997, 46 (04) :701-710
[9]  
GARB MM, 2000, DIABETES CARE, V23, P1108
[10]  
Gavin JR, 1999, DIABETES CARE, V22, pS5